8ZF Stock Overview
Operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Polarean Imaging plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.12 |
| 52 Week Low | UK£0.0005 |
| Beta | 0.29 |
| 11 Month Change | -96.67% |
| 3 Month Change | 0% |
| 1 Year Change | -98.55% |
| 33 Year Change | -99.92% |
| 5 Year Change | n/a |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8ZF | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.8% |
| 1Y | -98.6% | -5.0% | 9.1% |
Return vs Industry: 8ZF underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: 8ZF underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 8ZF volatility | |
|---|---|
| 8ZF Average Weekly Movement | 3,253.2% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8ZF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8ZF's weekly volatility has increased from 2503% to 3253% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 29 | Chris Von Jako | polarean.com |
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. It engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. The company also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measurement station, chest coil, and dose delivery inhalation bags.
Polarean Imaging plc Fundamentals Summary
| 8ZF fundamental statistics | |
|---|---|
| Market cap | €22.40m |
| Earnings (TTM) | -€8.14m |
| Revenue (TTM) | €1.78m |
12.6x
P/S Ratio-2.8x
P/E RatioIs 8ZF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8ZF income statement (TTM) | |
|---|---|
| Revenue | US$1.87m |
| Cost of Revenue | US$1.03m |
| Gross Profit | US$836.63k |
| Other Expenses | US$9.38m |
| Earnings | -US$8.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0071 |
| Gross Margin | 44.78% |
| Net Profit Margin | -457.39% |
| Debt/Equity Ratio | 0% |
How did 8ZF perform over the long term?
See historical performance and comparison